ARTICAIN IN ENDODONTICS: A REVIEW.

Dhiyouf Ali, Aravind R Kudva and Harish k. shetty.

INTRODUCTION:
Achieving profound pulpal anesthesia is a cornerstone in endodontic practice and dentistry. Profound pulpal anesthesia during the root canal procedure benefits not only the patient, for obvious reasons, but also the dentist who will be less stressed worrying about patient reactions or sudden movement during therapy. Achieving adequate anesthesia in patients can, at times, be a challenge. Clinicians constantly have sought an anesthetic solution with a better success rate than that of available anesthetics which has been demonstrated to be well below 100 percent.1

Root canal treatment has been described as significantly more painful for teeth with irreversible pulpitis and symptomatic apical periodontitis compared with teeth with necrotic pulps and asymptomatic apical periodontitis. In addition, achieving profound pulpal anesthesia can be challenging in these cases. For example, anesthesia may be sufficiently profound to access the pulp chamber, but canal instrumentation can result in severe pain. In a survey of Diplomates of the American Board of Endodontic, 84% of respondents reported experiencing difficulties in anesthetizing acutely painful mandibular molars.

The inability to achieve pulpal anesthesia has been shown to increase a patient’s fear and anxiety, exacerbate systemic medical issues, extend the appointment duration, and generate doubt in the operator; any of these factors can contribute to the impression that receiving root canal treatments a painful procedure.

In the search for less allergic compounds with a faster onset, the amide-type local anesthetic lignocaine was synthesized by Swedish chemist Nils Löfgren in 1943 and marketed as lidocaine in 1949. Since then, other amide local anesthetics have been introduced and used clinically for their favorable onset time and duration, e.g., mepivacaine, prilocaine, bupivacaine, etidocaine, and ropivacaine. Among this group, articaine, originally synthesized as carticaine, entered dentistry practice in 1973. Epidural administration and comparison with lidocaine started in 1974. In 1984, it was released in Canada, followed by the UK in 1998, the rest of Europe and the US in 2000, and Australia in 2005. Currently, articaine 4% with adrenaline 5 μg/mL is widely used in dentistry.

Articaine:-
Articaine {4-methyl-3-[2-(propylamino)propionamido]-2-thiophenecarboxylate}, was synthesized in 1969 by Rushing, but not used clinically until the mid-1970s in Germany.

Unlike other amide local anesthetics articaine has a thiophene ring. This increases its lipid solubility to a value close to that of prilocaine and not surprisingly it is used in similar concentrations (2-4%). It has a low pKa and clinical
studies have confirmed a rapid onset of action. Protein binding is high and a prolonged duration might be expected. However, unlike other amide local anesthetics articaine contains an additional ester group, so that metabolism occurs in the plasma by non-specific cholinesterase’s as well as in the liver. The rapid onset of articaine has been demonstrated by Altman in ophthalmic blocks, where it may prove useful as ocular movement returns rapidly after the completion of surgery. In addition, the rapid fall in plasma levels will also reduce the risks of toxicity. However, in patients with known deficiency of plasma cholinesterase’s an alternative choice would be appropriate.\(^5\)

Articaine has been widely used in dental surgery. Dentists started to use articaine around 1977. In dentistry, articaine has been investigated extensively. Clinical trials comparing articaine mostly with lidocaine have varied in study design and site of action. The overwhelming majority of references in the literature describing the alleged neurotoxicity of articaine concern par aesthesia and prolonged numbness after dental procedures... Although there may be controversy regarding its safety and advantages in comparison to other local anesthetics, there is no conclusive evidence demonstrating neurotoxicity or significantly superior anesthetic properties of articaine for dental procedures The choice whether to use articaine or another local anesthetic is based on the personal preference and experiences of individual clinicians. Currently, articaine is available as a 4% solution containing 1:100,000 or 1:200,000 epinephrine. Clinical trials comparing 4% with 2% solutions show no clinical advantage of 4% over a 2% solution Recognizing the importance of providing profound anesthesia for patients undergoing invasive dental procedures, clinicians continually seek to identify an anesthetic solution that provides the highest success rate at an affordable cost.\(^6\)

Articaine can diffuse through soft and hard tissues more reliably than other LA so that maxillary buccal infiltration of articaine provides palatal soft tissue anesthesia.\(^7\) The basis for the prevalent use of articaine is due to the belief that it has better diffusion through soft tissue and bone, rapid onset, excellent quality of anesthesia, and lower degree of toxicity than lidocaine. Articaine provides complete anesthesia even by infiltration technique due to its superior tissue penetration capability.\(^8\) Lidocaine is the most widely used local anesthetic in medicine as well as dentistry. It is evident that extraction of the permanent maxillary tooth is possible with single buccal infiltration of 2% lidocaine without the need for palatal injection.\(^9\)

**Pharmacodynamic properties:-**
Articaine blocks nerve conduction by reversibly binding to the \(\alpha\)-subunit of the voltage-gated sodium channels within the inner cavity of the nerve, similar to other local anesthetics. Binding of articaine to the sodium channel reduces sodium influx so that the threshold potential will not be reached and impulse conduction stops. The blocking action of articaine on the sodium channel is state dependent: it has the highest affinity for the open state, an intermediate affinity for the inactivated state, and the lowest affinity for the resting state.\(^10\)

The degree of neuronal block is affected by the diameter of the nerve. Larger-diameter fibers (touch/pressure/motor) require higher concentrations of local anesthetic compared with small myelinated fibers (pain afferents).\(^6\) Articaine is lipid soluble, highly protein-bound (94%), and has a dissociation constant (pKa) of 7.8. Articaine is an intermediate-potency, short-acting local anesthetic with a fast onset of action.\(^11\)

**Pharmacokinetic properties:-**
**Absorption and distribution:-**
Local anesthetic drugs are administered to the areas around the nerves to be blocked, e.g., the skin, subcutaneous tissues, retro bulbar, intrathecal, and epidural spaces. Some of the drug will be absorbed into the systemic circulation; how much will depend on the vascularity of the area to which the drug has been applied and intrinsic effects of the drug or its additives on vessel diameter. Articaine, like most local anesthetics at concentrations that are used clinically, has a vasodilatory effect, increasing its systemic absorption. This is countered in preparations with epinephrine 1:60,000, 1:100,000, and 1:200,000 (5 \(\mu\)g/mL).\(^12\)

The distribution of the drug is influenced by the degree of tissue and plasma protein binding of the drug. The more protein-bound the agent, the longer the duration of action, as free drug is more slowly made available for metabolism. Based on its physicochemical and stereochemical properties, protein binding of articaine is 94%.\(^13\)

**Metabolism and elimination:-**
The molecular structure of articaine is characterized by having both lipophilic and hydrophilic ends connected by a hydrocarbon chain. The “CO linkage” between the hydrocarbon chain and the lipophilic aromatic ring classifies
articaine as being an ester local anesthetic, in which the link is metabolized in the serum by plasma cholinesterase. Articaine is quickly metabolized via hydrolysis into its inactive metabolite articainic acid, which is partly metabolized in the kidney into articainic acid glucuronide. The pharmacokinetics and metabolism of articaine have been studied in ten patients undergoing intravenous regional anesthesia using 40 mL articaine 0.5% (200 mg). During tourniquet application and regional analgesia, 55% of the administered dose was already hydrolyzed by plasma (20%) and tissue (35%) esterase activity. After releasing the tourniquet, articaine and its metabolite articainic acid appeared in the blood; articaine was rapidly eliminated with a half-life of approximately 60 minutes. Low systemic concentrations and rapid metabolism of articaine also have been observed in a study during and after tumescent local anesthesia (infusion) for liposuction using dosages up to 38.2 mg/kg body weight. Average maximum plasma concentrations Cmax) for articaine ranged from 136 (hips) to 264 ng/mL (abdomen); the average extent of absorption (AUC) ranged from 827 to 2203 ng•h/mL. The corresponding Cmax and AUC values for articainic acid were substantially higher, ranging from 1719 to 7292 ng/mL and from 13,464 ng•h/mL (chin) to 74,962 ng•h/mL (abdomen), respectively. In liposuction, part of the applied drug is removed in the aspirate, and around 30% of the infused dose was recovered in the plasma is preserved in their erythrocytes.

Toxicity and safety:-
All commonly used local anesthetics produce neurotoxicity in a concentration-dependent manner. Proposed causes for neurological deficits are neural ischemia (due to local vasoconstriction caused by the local anesthetic itself or by epinephrine) or inflammation.

Clinical profiles of neurotoxicity of articaine have been based on the reported incidence of transient neurologic syndrome after spinal anesthesia and paresthesia in dentistry. Articaine acquired from Sanofi Aventis (Paris, France) and other local anesthetics in relative experimentally effective anesthetic concentrations have been investigated for their potency to induce apoptosis in human tumor cells (SHEP neuroblastoma cells). The observed neurotoxicity correlates with the lipophilicity and therefore with the potency of the local anesthetic. The concentrations of local anesthetics that induced apoptosis in their model are within the same range as those observed intrathecally after single-shot spinal anesthesia in primates and in sciatic nerves of rodents during nerve blockade.

Clinical signs are perioral and tongue parenthesis, a metallic taste, and dizziness, passing into slurred speech, diplopia, tinnitus, confusion, restlessness, and muscle twitching progressing to neuronal depression and leading to convulsions and coma. The severity of cardiovascular and central nervous system toxicity is directly related to the local anesthetic potency, dose, and rate of administration. In this context, one has to distinguish acute toxicity caused by accidental intravascular administration from toxicity caused by systemically absorbed local anesthetic. Maximum doses of local anesthetics lack scientific justification; as a consequence, the recommended highest dose of articaine, assumed to be around 4–7 mg/kg, has to be interpreted as an important guide number. In general, the site of local anesthetic injection in combination with patient-related factors and their expected influence on the pharmacodynamic or pharmacokinetic change are important reasons to reduce the dose, especially for repeated or continuous administration.

If administration of articaine or another local anesthetic is done expertly and cautiously, LAST can occur. Treatment options for LAST, particularly local anesthetic cardiotoxicity, have recently improved in the form of intravenous lipid emulsion therapy (an initial bolus of 1.5 mL/kg of a 20% solution followed by an infusion of 0.25 mL/kg/minute). Lipid emulsion is a reasonably well-tolerated and effective treatment, especially when LAST is caused by a lipophilic local anesthetic like articaine. The effects of articaine and ropivacaine on the components of intracellular Ca2+ handling, the cause of negative isotropic actions, were studied and compared in canine ventricular myocardium. Under conditions of normal application, both articaine and ropivacaine are free of cardio depressant effects.

Articaine is the center of heated discussions among dental surgeons as it has a faster onset and higher success rates than lidocaine as well as it has been demonstrated to increase the risk of paresthesia which could not be confirmed in a recent study. Articaine has been shown to be a significantly better anesthetic agent as compared to lidocaine for infiltrations.
The chemical composition of articaine contains a unique thiophene ring instead of the benzene ring found in lidocaine and other amide local anesthetics. This difference increases lipid solubility, thereby increasing diffusion through the lipid membrane of the epineurium, which purportedly explains its faster onset and higher success rate when compared with lidocaine.\[^{35, 36}\]

Teeth with irreversible pulpitis have shown greater difficulty in achieving anesthesia during endodontic treatment. In addition, achieving anesthesia in mandibular molar teeth with irreversible pulpitis is more difficult compared with other posterior teeth with the same condition.\[^{37}\]

Articaine is an anesthetic solution that was approved by the Food and Drug Administration for use in dentistry in the United States in 2000.\[^{38}\] Articaine is claimed to provide faster onset and longer duration of pulp anesthesia compared with lidocaine.\[^{39}\] Several investigations have compared the anesthetic efficacy of articaine with other anesthetic agents.\[^{40-45}\] The results of these studies have shown no significant difference between articaine and lidocaine when used for IANB injections.\[^{40-45}\]

### Available local anesthetic solutions.

| DURATION OF ACTION            | SOLUTION                              | INFILTRATION (PULPAL) | NERVE BLOCK (PULPAL) | DURATION OF EFFECT IN SOFT TISSUE |
|-------------------------------|---------------------------------------|-----------------------|----------------------|-----------------------------------|
| **Short Duration, Plain**     | Lidocaine hydrochloride (HCl) 2 Percent | 5 minutes             | Not Indicated        | 2 hours                           |
|                               | Mepivacaine HCl 3 percent             | 20 to 30 Minutes      | 45 to 65 Minutes     | 2 to 3 hours                      |
|                               | Prilocaine HCl 4 percent              | 10 to 15 minutes      | 45 to 65 minutes     | 3 to 4 hours                      |
| **Normal Duration, With Vasoconstrictor** | Articaine HCl 4 percent with epinephrine 1:100,000 | 60 to 75 Minutes      | Up to 120 Minutes    | 3 to 5 hours                      |
|                               | Articaine HCl 4 percent With epinephrine 1:200,000 | 60 to 75 Minutes      | Up to 120 Minutes    | 3 to 5 hours                      |
|                               | Lidocaine HCl 2 percent With epinephrine 1:50,000 | 55 to 65 Minutes      | 80 to 90 Minutes     | 3 to 5 hours                      |
|                               | Lidocaine HCl 2 percent With epinephrine 1:100,000 | 55 to 65 Minutes      | 80 to 90 Minutes     | to 5 hours                        |
|                               | Mepivacaine HCl 2 percent With levonordefrin 1:20,000 | 40 to 60 Minutes      | 60 to 90 Minutes     | 3 to 5 hours                      |
|                               | Prilocaine HCl 4 percent With epinephrine 1:200,000 | 35 to 45 minutes      | 50 to 70 minutes     | 3 to 6 hours                      |
| **Long Duration**             | Bupivacaine HCl 0.5 percent with epinephrine 1:200,000 | Up to 7 hours         | Up to 7 hours        | Up to 12 hours                    |

\[^{1625-1633}\]
April 2000. Articaine is available as a 4 percent solution, and lidocaine is available as a 2 percent solution. Both can be combined with various concentrations of vasoconstrictors. Articaine contains a thiophene ring, instead of the benzene ring found in lidocaine and other amide local anesthetics; this allows the molecule to diffuse more readily through the nerve membrane owing to increased lipid solubility. A second molecular difference is the ester linkage incorporated into the articaine molecule, which results in hydrolysis of articaine by plasma esterase’s. Ninety to 95 percent of articaine is metabolized in the blood by plasma esterase’s, with the remainder being broken down in the liver, whereas approximately 90 percent of lidocaine is metabolized by the liver. The articaine solution’s plasma half-life has been reported to be as short as 20 minutes.

Although investigators have designed various clinical trials to compare articaine with a variety of other available anesthetic solutions, published data do not support a clear superiority of articaine in terms of anesthetic efficacy. Thus, clinicians still may wonder which anesthetic solution will afford them the best chance of success for a given procedure, particularly in cases of irreversible pulps.

Clinical studies on articaine and lignocaine have focused on the time to onset of clinical anesthesia, dose, duration, depth of anesthesia along with the safety and efficacy profile, and mean time of onset in children versus adults, infiltrations and nerve blocks, conventional syringe versus computer controlled drug delivery system Single Tooth Anesthesia Wand (STA-Wand) administered for restorative procedures and extractions. The available literature on articaine confirms the effectiveness of conventional single buccal infiltrations in maxillary primary molar extractions replacing the need of painful palatal injections which is usually required whenever conventional infiltration anesthesia with lignocaine is preferred. Interestingly, the literature available on the efficacy of articaineintraligamentary injections administered with Wand for pulpectomy procedures on primary molar teeth seems to be limited, and sometimes, the intraligamentary injections have also been considered to overcome the drawbacks of nerve block particularly when there is a need for treatment procedures in bilateral quadrants at the same appointment.

Inferior alveolar nerve block and buccal infiltration or inferior alveolar nerve block and periodontal ligament injection using 4% articaine/HCl with 1:100,000 epinephrine could result in a high rate of anesthetic success in patients with irreversible pulps in the mandibular first molar. Both offer effective strategies for practitioners and patients. Neither combination, however, provided total anesthetic success during irreversible pulps treatments.

The use of 4% articaine is popular among dentists owing to its short plasma half-life. However, some researchers have suggested that this high concentration may be associated with nerve damage.

No easy solution has been identified for successfully anesthetizing all patients with vital mandibular painful teeth diagnosed with symptomatic irreversible pulpitis patients clinical condition are more difficult to anesthetize for various reason, all of which are not fully understood. Some of the reason described in the research literature are altered resting potentials and described excitability threshold of inflamed nerves, terodotoxin-resistant sodium channels increased expression of sodium channels in irreversibly inflamed pulps and apprehensive patients with lower pain thresholds. The reason most often cited but least likely to hold true is lowered pH of inflamed tissue. The theory hypothesizes that lowered pH reduces the amount of base form of the anesthetic available to penetrate the membrane ther by preventing anesthesia. This is not best explanation for failure with inferior alveolar nerve block (IANB) when the injection is not given at the primary site of inflammation. Likely, this is more complicated neuronal process.inflammation and bacterial insult can lead to sprouting of nerve fibers, increased expression of neuropeptides such as substance P and calcitonin gene related peptide, and the release of inflammatory mediators such as prostaglandins E2, prostaglandins F2a, interleukins 1 and 6, and tumor necrosis factor. This can also lead to excitability of nociceptor isoforms. This clinical condition may include neuronal plasticity allodynia, hyperalgesia peripherally and centrally, and central sensitization. These factors may help to explain why local anesthesia is not always effective when patients are in pain.

In a study by Arrow et al, although the inferior alveolar nerve block with Articaine was more successful than that with Lidocaine, no significant differences were observed in the mandibular buccal infiltration technique between the two anesthetic agents.

It is a mistake if a dentist assumes that soft tissue anesthesia is a sign of successful pulp anesthesia. Soft tissue anesthesia after the administration of an IANB only indicates that the injection has been administered at the correct
site, but it does not guarantee pulp anesthesia. Successful pulp anesthesia success is only achieved if no or minimal pain is reported by the patient during access cavity preparation and root canal instrumentation. One of the suggested methods to overcome the failure of anesthesia after the administration of an IANB is to increase the volume of the anesthetic solution. Most of the previous investigations have reported that increasing the volume has no significant effect on anesthesia success. However, these studies have only used lidocaine as the anesthetic solution.

Irreversible pulpitis, which is a severe damage to the pulp via bacteria in the vital dental pulp, would cause necrosis or death to pulp tissues, and thus leads to very intolerable severe spontaneous pain and forces patients to seek immediate treatment. Articaine was the second most used dental local anesthetic in the US, only after lidocaine. Articaine is generally effective in providing patients with pain-free treatment because of its high liposolubility which facilitates the diffusion of the anesthetic solution to the teeth, but local anesthetic failure is still a concern in treatment of irreversible pulpitis.

The 4% articaine with 1:100,000 epinephrine resulted in shorter onset time in pulpal anesthesia than 2% lidocaine with 1:100,000 epinephrine. The onset time of anesthesia is directly related to the rate of epineural diffusion, which is correlated with the percentage of drug in the base form, which is proportional to the pKa of that agent. pKa was 7.8 in the articaine group, and was 7.9 in the lidocaine group.

The intraosseous injection seems to raise the success rate to a reliable extent as shown in some previous studies. It is not a preferable technique because it requires special equipment, drilling of the cortical bone, and preparing a site for administration of the anesthetic solution. The intraligamentary injections have a short duration of action and may increase postoperative pain. The intraosseous and intraligamentary techniques are effective in raising anesthesia levels in difficult anesthetic situations; however, it would be beneficial if similar results could be achieved by simpler options such as the infiltration technique. This technique has been studied extensively in asymptomatic teeth.

Some of these studies performed a comparison between lidocaine and articaine. The results of some revealed no significant differences between the 2 anesthetics, whereas the findings of others suggested that articaine was superior to lidocaine in raising pulpal anesthesia in mandibular teeth. In a study by Kanna et al., lidocaine and articaine were compared in maxillary teeth with irreversible pulpitis. The results of their study showed no significant differences between these anesthetics.

In a study by McEntire et al., the anesthetic efficacy of 4% articaine with 1:200,000 epinephrine was shown to be comparable to 4% articaine with 1:100,000 epinephrine in a primary mandibular buccal infiltration of asymptomatic mandibular first molars.

In a study by Poorni et al. on mandibular molars with irreversible pulpitis, the efficacy of an IANB with articaine or lidocaine showed similar success rates compared with a buccal infiltration with articaine that had not been supplemented with an IANB. This may bring up the point that the infiltration technique could be a reliable choice of anesthesia.

In a study by Matthews et al. supplemental articaine infiltration injections were administered after failure of lidocaine IANB in posterior mandibular teeth with irreversible pulpitis. They found that the articaine infiltration injection was successful 58% of the time. Aggarwal et al. compared lidocaine and articaine infiltration injections that were applied on both buccal and lingual sides of posterior mandibular teeth with irreversible pulpits after lidocaine IANB. They found the success rates of lidocaine and articaine to be 47% and 67%, respectively. Even though these studies investigated mandibular teeth with irreversible pulpits, they had performed the IAN blocks by using lidocaine, and the obtained results would not predict pulpal anesthesia in all patients.

**Conclusion:**
Articaine seems to raise anesthetic success more effectively compared with other local anesthetics used in dentistry. In cases of persistent pulpal pain despite successful mandibular block anesthesia, supplementary infiltration with articaine instead of lidocaine has 3.5 times greater likelihood of achieving successful anesthesia. The clinical evidence concludes that 4% articaine with 1:100,000 epinephrine is superior in increasing the success rate of local anesthesia and pain control at the injection phase and treatment phase. This solution also results in shorter onset time of pulpal anesthesia and is superior in decreasing the percentage of patients undergoing adverse events compared.
with 2% lidocaine with 1:100 000 epinephrine Achieving profound pulpal anesthesia in all patients remains a future goal requiring further investigation.

References:
1. John M, Nusstein, DDS, MSa, Al Reader, DDS, MSb, Melissa Drum, DDS, MS. Local Anesthesia Strategies for the Patient With a “Hot Tooth. Dent Clin N Am 54 (2010) 237–247.
2. Segura-Egea JJ, Cisneros-Cabello R, Llamas-Carreras JM, Velasco-Ortega E. Pain associated with root canal treatment. Int Endod J 2009;42:614–20.
3. Fleury AA. Local anesthesia failure in endodontic therapy: the acute inflammation factor. Compendium 1990;11:210, 212, 214 passim.
4. Quint JH. The failure of local anesthesia in acute inflammation. Br Dent J 1981;151:214.
5. Wallace JA, Michanowicz AE, Mundell RD, Wilson EG. A pilot study of the clinical problem of regionally anesthetizing the pulp of an acutely inflamed mandibular molar. Oral Surg Oral Med Oral Pathol 1985;59:517–21.
6. Marc snoeck.articaine: a review of its use for local and regional anesthesia. dovepressjournal 25 june 2012.
7. Malamed S. Handbook of Local Anesthesia. 6th ed. St. Louis, MO: CV Mosby; 2013.
8. Oertel R, Richter K, Weile K, Gramatté T, Berndt A, Feller K. A simple method for the determination of articaine and its metabolite articainic acid in dentistry: Application to a comparison of articaine and lidocaine concentrations in alveolus blood. Methods Find Exp Clin Pharmacol 1993;15:541–7.
9. Sekhar GR, Nagaraju T, KolliGiri, Nandagopal V, Sudheer R, Sravan. Is palatal injection mandatory prior to extraction of permanent maxillary tooth: A preliminary study. Indian J Dent Res 2011;22:100–2.
10. Wang GK, Calderon J, Jaw SJ, Wang SY. State-dependent block of Na+ channels by articaine via the local anesthetic receptor. J Membr Biol. 2009;229:1–9.
11. McLure HA, Rubin AP. Review of local anaesthetic agents. Minerva Anestesiol. 2005;71:59–74.
12. Sack U, Kleemann PP. Intraoral conduction anesthesia with epinephrine-containing local anesthetics and arterial epinephrine plasma concentration. Anesth Pain Control Dent. 1992;1:77–80.
13. Mather LE, Tucker GT. Properties, absorption, and disposition of local anesthetic agents. In: Cousins MJ, Carr DB, Horlocker TT, Bridenbaugh PO, editors. Neural Blockade in Clinical Anesthesia and Pain Medicine, 4th ed. Philadelphia: Wolters Kluwer/Lippincott Williams and Wilkins; 2009:48–95.
14. Vree TB, Gielen MJ. Clinical pharmacology and the use of articaine for local and regional anesthesia. Best Pract Res Clin Anaesthesiol. 2005;19:293–308.
15. Vree TB, Simon MA, Gielen MJM. Booij LHDJ. Regional metabolism of articaine in 10 patients undergoing intravenous regional anaesthesia during day case surgery. Br J Clin Pharmacol. 1997;44:29–34.
16. Grossmann M, Sattler G, Pistner H, et al. Pharmacokinetics of articaine hydrochloride in tumescent local anaesthesia with lidocaine containing local anesthetics and epinephrine. J Clin Pharmacol. 2004;44:1282–1289.
17. Calvo R, Carlos R, Erill S. Effects of disease and acetazolamide on procaine hydrolysis by red cell enzymes. Clin Pharmacol Ther. 1980;27:175.
18. Gerner P, Strichartz GR. Sensory and motor complications of local anesthetics. Muscle Nerve. 2008;37:421–425.
19. Zaric D, Christiansen C, Pace NL, Punjasawadwong Y. Transient neurologic symptoms (TNS) following spinal anaesthesia with lidocaine versus other local anaesthetics. Cochrane Database Syst Rev. 2005;2:CD003006.
20. Pogrel MA. Permanent nerve damage from inferior alveolar nerve blocks – an update to include articaine. J Calif Dent Assoc. 2007;35:271–273.
21. Werdehausen R, Fazeli S, Braun S, et al. Apoptosis induction by different local anesthetics in a neuroblastoma cell line. Br J Anaesth. 2009;103:711–718.
22. Denson DD, Bridenbaugh PO, Turner PA, Phero JC. Comparison of neural blockade and pharmacokinetics after subarachnoid lidocaine in the rhesus monkey. II: Effects of volume, osmolality, and baricity. Anesth Analg. 1983;62:995–1001.
23. Nakamura T, Popitz-Bergez F, Birkenes J, Strichartz GR. The critical role of concentration for lidocaine block of peripheral nerve in vivo: studies of function and drug uptake in the rat. Anesthesiology. 2003;99:1189–1197.
24. Mather LE, Copeland SE, Ladd LA. Acute toxicity of local anesthetics: underlying pharmacokinetic and pharmacodynamic concepts. Reg Anesth Pain Med. 2005;30:553–56.
25. Rosenberg PH, Veering BT, Urney WF. Maximum recommended doses of local anesthetics: a multifactorial concept. Reg Anesth Pain Med. 2004;29:564–575.
26. Wolf JW, Butterworth JF. Local anesthetic systemic toxicity: update on mechanisms and treatment. CurrOpinAnesthesiol. 2011;24:561–566.
27. Drasner K. Local anesthetic toxicity: optimal management to avoid neurotoxic injury and treat cardiac arrest. ASA Refresher Courses in Anesthesiology. 2011;39:33–40.
28. Malamed SF, Gagnon S, Leblanc D. Articaine hydrochloride: a study of the safety of a new amide local anesthetic. J Am Dent Assoc. 2001;132:177-85.
29. Haas DA, Lennon D. Local anesthetic use by dentists in Ontario. J Can Dent Assoc. 1995;61:297-304.
30. Pogrel MA. Permanent Nerve Damage From Inferior Alveolar Nerve Blocks-An Update to Include Articaine. J Calif Dent Assoc. 2007;35:271-3.
31. Robertson D, Nusstein J, Reader A, Beck M, McCartney M. The anesthetic efficacy of articaine in buccal infiltration of mandibular posterior teeth. J Am Dent Assoc. 2007;138:1104-12.
32. Evans G, Nusstein J, Drum M, Reader A, Beck M. A Prospective, Randomized, Double-blind Comparison of Articaine and Lidocaine for Mandibular Infiltrations. J Endod. 2008;34:389-93.
33. Haase A, Reader A, Nusstein J, Beck M. Comparing anesthetic efficacy of articaine versus lidocaine as a supplemental buccal infiltration of the mandibular first molar after an inferior alveolar nerve block. J Am Dent Assoc. 2008;139:1228-35.
34. Malamed SF, Gagnon S, Leblanc D. Articaine hydrochloride: a study of the safety of anew amide local anesthetic. J Am Dent Assoc 2001;132:177–85.
35. Oertel R, Rahn R, Kirch W. Clinical pharmacokinetics of articaine. Clin Pharm. 2001;33:417–25
36. Parirork M, V Abbott P. Various strategies for pain-free root canal treatment. Iran Endod J 2014;9:1–14
37. Paxton K, Thome DE. Efficacy of articaine formulations: quantitative reviews. Dent Clin North Am 2010;54:643–53. 14.
38. Tortamano IP, Siviero M, Lee S, et al. Onset and duration period of pulpal anesthesia of articaine and lidocaine in inferior alveolar nerve block. Braz Dent J 2013;24: 371–4
39. Claffey E, Reader A, Nusstein J, et al. Anesthetic efficacy of articaine for inferior alveolar nerve blocks in patients with irreversible pulpitis. J Endod 2004;30:568–71. 16.
40. Mikesell P, Nusstein J, Reader A, et al. A comparison of articaine and lidocaine for inferior alveolar nerve blocks. J Endod 2005;31:265–70. 17.
41. Tortamano IP, Siviero M, Costa CG, et al. A comparison of the anesthetic efficacy of articaine and lidocaine in patients with irreversible pulpitis. J Endod 2009;35: 165–8.
42. Ashraf H, Kazem M, Dianat O, Noghrehkar F. Efficacy of articaine versus lidocaine in block and infiltration anesthesia administered in teeth with irreversible pulpitis: a prospective, randomized, double-blind study. J Endod 2013;39:6–10. 19.
43. Monteiro MR, Groppo FC, Haiter-Neto F, et al. 4% articainebuccal infiltration versus 2% lidocaine inferior alveolar nerve block for emergency root canal treatment in mandibular molars with irreversible pulps: a randomized clinical study. IntEndod J 2015;48:145–52.
44. Rahul G, Nandlal B, Prashanth. Pain perception and procedural tolerance with computer controlled and conventional local anesthetic technique: An in vivo comparative study. Indian J Pain 2014;28:143–8.
45. Tortamano IP, Siviero M, Lee S, Sampaio RM, Simone JL, Rocha RG. Onset and duration period of pulpal anesthesia of articaine and lidocaine in inferior alveolar nerve block. Braz Dent J 2013;24:371–4
46. Kolli NK, Nirmala SV, Nuvvula S. The Effectiveness of Articaine and Lidocaine Single Buccal Infiltration versus Conventional Buccal and Palatal Injection Using Lidocaine during Primary Maxillary Molar Extraction: A Randomized Control Trial. Anesth Essays Res 2017;11:160–4.
47. Adewumi A, Hall M, Guelmann M, Riley J. The incidence of adverse reactions following 4% septicaine (articaine) in children. Pediatr Dent 2008;30:424–8.
48. . Oztas N, Ulusu T, Bodur H, Dogan C. The wand in pulp therapy: An alternative to inferior alveolar nerve block. Quintessence Int 2005;36:559–64.
49. Song fan,wei-liangchen et al. anesthetic efficacy of inferior alveolar nerve block plus buccal infiltration or periodontal ligament injection with articaine in patient with irreversible pulpsities in mandibular first molar. Oral Surg Oral Med Oral Pathol Oral Radio Endod 2009;108:e89-e93)
50. Melissa Drum, DDS, MS; Al Reader, DDS, MS; John Nusstein, DDS, MS; Sara Fowler, DMD, MS Successful pulpal anesthesia for symptomatic irreversible pulpitis. 8 JADA 148(4) April 2017
51. Arrow P. A comparison of articaine 4% and lignocaine 2% in block and infiltration analgesia in children. Aust Dent J. 2012;57(3):325-33.
52. Parirork M, V Abbott P. Various strategies for pain-free root canal treatment. Iran Endod J 2014;9:1–14.
53. Vreeland DL, Reader A, Beck M, et al. An evaluation of volumes and concentrations of lidocaine in human inferior alveolar nerve block. J Endod 1989;15: 6–12. 21. Nuussen J, Reader A, Beck FM.
54. Anesthetic efficacy of different volumes of lidocaine with epinephrine for inferior alveolar nerve blocks. Gen Dent 2002;50:372–5. 22.
55. Parirak M, Satvati SA, Sharihi R, et al. Efficacy of combining a buccal infiltration with an inferior alveolar nerve block for mandibular molars with irreversible pulpitis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2010;109: 468–73. 23.
56. Wali M, Drum M, Reader A, Nuussen J. Prospective, randomized single-blind study of the anesthetic efficacy of 1.8 and 3.6 milliliters of 2% lidocaine with 1:50,000 epinephrine for inferior alveolar nerve block. J Endod 2010;36:1459–62. 24.
57. Aggarwal V, Singla M, Miglani S, et al. Comparative evaluation of 1.8 mL and 3.6 mL of 2% lidocaine with 1:200,000 epinephrine for inferior alveolar nerve block in patients with irreversible pulpitis: a prospective, randomized single-blind study. J Endod 2012;38:753–6. 25.
58. Fowler S, Reader A. Is a volume of 3.6 mL better than 1.8 mL for inferior alveolar nerve blocks in patients with symptomatic irreversible pulpitis? J Endod 2013;39: 970–2
59. Li C, Yang X, Ma X, Li L, Shi Z. Preoperative oral nonsteroidal anti-inflammatory drugs for the success of the inferior alveolar nerve block in irreversible pulpitis treatment: a systematic review and meta-analysis based on randomized controlled trials. Quintessence Int 2012; 43: 209–19.
60. Malamed SF. Handbook of local anesthesia. 6th ed. Saint Louis, MO: Mosby; 2012.
61. Brandt RG, Anderson PF, McDonald NJ, Sohn W, Peters MC. The pulpal anesthetic efficacy of articaine versus lidocaine in dentistry. J Am Dent Assoc 2011; 142: 493–504.
62. Bigby J, Reader A, Nuussen J, et al. Articaine for supplemental intraosseous anesthesia in patients with irreversible pulpitis. J Endod 2006;32:1044–7.
63. Hargreaves KM, Keiser K. Local anesthetic failure in endodontics: mechanisms and management. Endod Topics 2002;1:26–39.
64. McLean ME, Wayman BE, Mayhew RB. Duration of anesthesia using the periodontal ligament injection: a comparison of bupivacaine to lidocaine. Anesth Pain Control Dent 1992;1:207–13.
65. Haas DA, Harper DG, Saso MA, et al. Lack of differential effect by Ultracaine (articaine) and Citanest (prilocaine) in infiltration anaesthesia. J Can Dent Assoc 1991;57:217–23.
66. Haas DA, Harper DG, Saso MA, et al. Comparison of articaine and prilocaine anesthesia by infiltration in maxillary and mandibular arches. Anesth Prog 1990;37: 230–7.
67. Kanaa MD, Whitworth JM, Corbett IP, et al. Articaine and lidocaine mandibular buccal infiltration anesthesia: a prospective randomized double-blind cross-over study. J Endod 2006;32:296–8.
68. Robertson D, Nuussen J, Reader A, et al. The anesthetic efficacy of articaine in buccal infiltration of mandibular posterior teeth. J Am Dent Assoc 2007;138:1104–12.
69. Corbett IP, Kanaa MD, Whitworth JM, et al. Articaine infiltration for anesthesia of mandibular first molars. J Endod 2008;34:514–8.
70. Ung YIL, Kim JH, Kim SE, et al. An evaluation of buccal infiltrations and inferior alveolar nerve blocks in pulp anesthesia for mandibular first molars. J Endod 2008;34:11–3.
71. Meechan JG, Kanaa MD, Corbett IP, et al. Pulpal anaesthesia for mandibular permanent first molar teeth: a double-blind randomized cross-over trial comparing buccal and buccal plus lingual infiltration injections in volunteers. Int Endod J 2006;39: 764–9.
72. Kanaa MD, Whitworth JM, Meechan JG. A comparison of the efficacy of 4% articaine with 1:100,000 epinephrine and 2% lidocaine with 1:80,000 epinephrine in achieving pulp anesthesia in maxillary teeth with irreversible pulpitis. J Endod 2012;38:279–82.
73. McEntire M, Nuussen J, Drum M, et al. Anesthetic efficacy of 4% articaine with 1:100,000 epinephrine versus 4% articaine with 1:200,000 epinephrine as a primary buccal infiltration in the mandibular first molar. J Endod 2011;37: 450–4.
74. Poomi S, Venishakob B, Senthilkumar AD, et al. Anesthetic efficacy of four percent articaine for pulpal anesthesia by using inferior alveolar nerve block and buccal infiltration techniques in patients with irreversible pulpitis: a prospective randomized double-blind clinical trial. J Endod 2011;37:1603–7.
75. Matthews R, Drum M, Reader A, et al. Articaine for supplemental buccal mandibular infiltration anesthesia in patients with irreversible pulpitis when the inferior alveolar nerve block fails. J Endod 2009;35:343–6.
76. Aggarwal V, Jain A, Kabi D. Anesthetic efficacy of supplemental buccal and lingual infiltrations of articaine and lidocaine after an inferior alveolar nerve block in patients with irreversible pulpitis. J Endod 2009;35:925–9.